Join the Magic Mushroom Revolution

Hypha Labs (OTCQB: FUNI) produces a mushroom accelerator capable of accelerating and improving the at-home growth process for functional mushrooms. Our product decreases contamination risk while cutting the time it takes to grow these fungi from 90 days to under 10, allowing customers to enjoy the health benefits of functional mushrooms.

First Mover Technology:
Hypha Labs has developed a patent-pending mushroom accelerator that revolutionizes the cultivation of functional mushrooms. This technology significantly reduces the cultivation time from 90 days to under 10 days, offering a user-friendly, compact solution that allows consumers to grow high-quality mushroom compounds at home. The proprietary nature of this technology sets Hypha Labs apart from traditional methods, providing a substantial competitive advantage in the market.
‍
Massive Untapped Market:
The functional mushroom market is experiencing explosive growth, surpassing $34 billion in 2023 and projected to reach $65 billion by 2030, with a CAGR of 12.5%. This growth is driven by increasing consumer awareness of the health benefits associated with functional mushrooms, especially in mental health and wellness. Investing in Hypha Labs offers a unique opportunity to be part of this burgeoning market as it expands.

Hypha Labs employs a classic razor-blade business model, selling the mushroom accelerator and proprietary cultivation kits. This model not only ensures initial revenue from the sale of the mushroom accelerator but also creates a steady stream of recurring revenue from the ongoing sale of cultivation kits. This dual revenue stream positions the company for sustainable growth and profitability, making it an attractive investment opportunity.

The product is still in development, so we don’t have traction to lean on. But the growth of the functional mushroom market highlights the booming demand for mushrooms, and Hypha’s first-of-its-kind tech makes enjoying their benefits easier than ever.

Launching the product and generating sales will be a big deal.

It’s a new market and they leveraged their expertise to develop and protect this technology first.

You can review all of Hypha Labs’s SEC Filings, including the offering circular for the Regulation A+ offering, here. 

The offering price is $0.20 per unit (Each Unit consisting of one share of Series D Preferred Stock (the "Series D Preferred Stock") and one Common Stock Purchase Warrant (the "Warrants")) and the minimum investment amount for this round is $1,000 plus a 2% investor fee.

Click “Invest Now” anywhere on this site, or follow this link. You will be directed to view the subscription agreement and complete an investment.

Investors can purchase shares via credit card, bank-to-bank payments, or express wires (reconciled in real-time).

This offering is open to both accredited and non-accredited investors. If you are a non-accredited investor, please note that you cannot invest more than 10% of the greater of your annual income or net worth.

According to the SEC, an individual accredited investor can be defined as the following: 

An accredited investor, in the context of a natural person, includes anyone who: earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR holds in good standing a Series 7, 65 or 82 license. 

Additionally, an accredited investor as an entity can be defined as the following: 
1. A trust is considered to be an accredited investor if its assets exceed $5 million, it is not created to purchase the securities and it is directed by a sophisticated person; or 
2. An entity is an accredited investor if its investment exceeds $5 million and it is not created to purchase securities. 
3. An entity in which all equity owners are accredited investors. 

If your credit card payment was declined, please call your credit card provider to pre-authorize the transaction. Additionally, if your bank-to-bank transfer via ACH has failed, it is recommended that you contact your bank for more information.

If you have forgotten your password, please use the “Forgot your password?” functionality found below the DealMaker sign-in page. If you are locked out of your account, please contact info@dealmaker.tech for assistance.

To change your email address, please navigate to the top-right corner of your Dashboard. Within your profile settings, you can change the email address associated with your account. If you would like to merge investments to a pre-existing account, under a different email address, please contact info@dealmaker.tech for assistance. Please specify the applicable email addresses to be changed. For investor security, you will be asked to verify that you have access to the applicable accounts.

You can specify whether you are investing as an individual, or as a corporation/trust/custodial. Upon selecting any of the non-individual options, you will be prompted to enter relevant information and populate your subscription agreement accordingly.

1) Funding Processed:  Your investment funding status will update upon receipt of your funds. If paying by bank-to-bank transfer, your payment will initially appear as pending, and will either clear or fail within five business days. If paying by wire domestically, your wire should be reconciled within one business day. International wires vary. Once funds are received, it can take approximately [1-2 weeks] *customize per issuer to process your investment completely.
 
2) Identity Processed: In some instances, we may reach out to you requesting additional information in order to verify your identity & finish processing your investment, which may increase the overall processing time. 
‍
3) Subscription Confirmation: Once your investment has been fully processed and confirmed, you will receive a notification when your subscription agreement has been accepted.

Please note that if your securities are being distributed through the DealMaker platform, you will receive a digital certificate or DRS statement from the issuer’s transfer agent, uploaded to your investment portal. No paper share certificates are distributed via DealMaker.   

Currently, the deadline for the offering is [INSERT DATE]. We may close the offering earlier than the deadline in the offering materials, for example, if we reach the target offering amount prior to the deadline.

For more information regarding your investment in this offering, please contact our investor support team at: invest@hyphalabs.com

You can search the DealMaker knowledge base for more information here, or contact investor support at info@hyphalabs.com

Yes. Securities sold in a Regulation A+ offering are not considered “restricted securities” under Securities Act Rule 144. As a result, sales of securities by persons who are not affiliates of the issuer are not subject to any transfer restrictions.    

Investors need to check with a brokerage account representative to determine whether their provider will allow for the securities to be (i) directly deposited to a brokerage account or (ii) transferred into such account at a later day. The policies may vary between different providers.